|Place of Origin:||China|
|Model Number:||2.5mg, 5mg / puff, 30 puffs|
|Minimum Order Quantity:||10, 000 bottles|
|Packaging Details:||one bottle/box|
|Payment Terms:||L/C, T/T|
|Supply Ability:||80, 000 bottles per day|
|Product:||Zolmitriptan Nasal Spray||Specification:||2.5mg, 5mg / Puff, 30 Puffs|
Zolmitriptan Nasal Spray Aerosol Medication Synthetic Tryptamines White Powder
Zolmitriptan Nasal Spray 2.5mg, 5mg / puff, 30 puffs Aerosol Medication
Product : Zolmitriptan Nasal Spray
Specification : 2.5mg, 5mg / puff, 30 puffs
Standard : USP
Packing : one bottle/box
Zolmitriptan is a synthetic tryptamine derivative and appears as a white powder that is readily soluble in water.
For the acute treatment of adult migraine with or without auras.
Zolmitriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptors. It is structurally and pharmacologically related to other selective 5-HT1B/1D receptor agonists, and has only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Zolmitriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Zolmitriptan in humans.
Mechanism of action
Zolmitriptan binds with high affinity to human 5-HT1B and 5-HT1D receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.